Status:
COMPLETED
Monitoring Serologic Response to Severe Acute Respiratory Syndrome-2 (SARS-COV-2)/COVID-19 in Children
Lead Sponsor:
Connecticut Children's Medical Center
Collaborating Sponsors:
The Jackson Laboratory
Food and Drug Administration (FDA)
Conditions:
COVID-19
SARS-CoV-2
Eligibility:
All Genders
2-27 years
Brief Summary
Individuals susceptible to SARS-CoV-2 and the illness it causes (COVID-19) are comprised of heterogeneous populations with a large risk spectrum for more severe disease. Pre-existing risk factors for ...
Eligibility Criteria
Inclusion
- Patients aged 2 to 27 years inclusive
- Patients receiving biologic infusions for inflammatory or rheumatologic disorders at the Connecticut Children's Infusion Center, at a minimum frequency of 2 infusions over a 4 month period
- Consent/assent as indicated
- Have vein access placement as standard of care
Exclusion
- Patient and/or parent/legal guardian refused participation
- Inability to draw requisite blood sample for serum collection
Key Trial Info
Start Date :
May 15 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 10 2025
Estimated Enrollment :
472 Patients enrolled
Trial Details
Trial ID
NCT04838834
Start Date
May 15 2020
End Date
February 10 2025
Last Update
April 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Connecticut Children's Medical Center
Hartford, Connecticut, United States, 06106